Introduction: Proteomics could improve our understanding of the etiology of diabetes. We sought to identify proteomic signatures associated with incident diabetes.

Method: We used data from the Atherosclerosis Risk in Communities (ARIC) Study (visit 2, 1990-92) in midlife (ages 47-70y) . We examined associations of 4955 plasma proteins measured using an aptamer-based platform in 11341 participants (∼50% women, ∼25% Black) without prevalent diabetes. We divided the data into discovery (2/3) and validation (1/3) sets. We used multivariable Cox regression to examine protein associations with incident diabetes (diagnosis or medication) . Statistical tests were based on Bonferroni corrected p-values.

Results: In the discovery set (n=7907) , 1443 diabetes events accrued over a median (IQR 12, 21) years. We identified 568 proteins associated (p<0.05/4955) with incident diabetes after demographic adjustment and 162 proteins after additional adjustment for lifestyle and cardiometabolic risk factors (Figure) . In the validation set (n=3434, 723 events) , 78 of the 162 proteins were statistically significantly (p<0.05/162) associated with incident diabetes, including established (e.g. adiponectin, growth hormone receptor) and novel hits (e.g. apoplipoprotein F, carboxypeptidase M) .

Conclusions: We identified multiple established and novel proteins associated with incident diabetes in midlife.


M.R. Rooney: None. J. Chen: None. O. Tang: None. C.M. Ballantyne: Consultant; Abbott Diagnostics, Althera Pharmaceuticals, Amarin Corporation, Amgen Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca, Corvidia Therapeutics, Denka Seiken, ESPERION Therapeutics, Inc., Genentech, Inc., Gilead Sciences, Inc., Illumina, Matinas BioPharma Inc, Merck & Co., Inc., New Amsterdam, Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Diagnostics, Sanofi. Research Support; Abbott Diagnostics, Akcea Therapeutics, Amgen Inc., Arrowhead Pharmaceuticals, Inc., ESPERION Therapeutics, Inc., Ionis Pharmaceuticals, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals Inc., Roche Diagnostics. E. Boerwinkle: None. J. Echouffo Tcheugui: None. C.E. Ndumele: None. J.S. Pankow: None. P. Lutsey: None. L.E. Wagenknecht: None. M. Grams: None. E. Selvin: Other Relationship; Wolters Kluwer. J. Coresh: Consultant; Ltd. Research Support; National Institutes of Health.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at